Augmented expression of Ki-67 is correlated with clinicopathological characteristics and prognosis for lung cancer patients: an up-dated systematic review and meta-analysis with 108 studies and 14,732 patients

Table 5 Main results for meta-analysis between Ki-67 and clinicopathological features in lung cancer

Clinicopathological features	Study(n)	Pooled OR(95%CIs)	z	P	Heterogeneity			Publication bias
Clinicopathological features	Study(n)	Pooled OR(95%CIs)	z	P	I²	P	Estimated method	P
Age	19	1.246(1.039–1.494)	2.37	0.018	0.00%	0.967	Fixed-effect	0.234
Gender	26	1.874(1.385–2.535)	4.07	< 0.001	69.70%	0.000	Random-effect	1.000
Histological type	16	0.397(0.236–0.667)	3.49	< 0.001	81.20%	0.000	Random-effect	0.324
Differentiation	11	1.993(1.262–3.146)	2.96	0.003	66.30%	0.001	Random-effect	0.893
Pathologic stage	13	1.867(1.498–2.327)	5.56	< 0.001	23.10%	0.210	Fixed-effect	1.000
Tumor size	12	1.436(1.127–1.29)	2.93	0.003	0.00%	0.876	Fixed-effect	0.276
Tumor stage	11	1.287(0.882–1.877)	1.31	0.191	55.30%	0.013	Random-effect	0.086
Metastasis	4	2.609(0.667–10.204)	1.38	0.168	64.50%	0.038	Random-effect	0.428
Lymph node	23	1.653(1.285–2.127)	3.91	< 0.001	46.70%	0.008	Random-effect	0.876
TNM stage	8	1.497(1.053–2.126)	2.25	0.024	36.90%	0.134	Fixed-effect	0.187
Invasion	3	0.993(0.511–1.930)	0.02	0.984	14.20%	0.312	Fixed-effect	0.308
Smoking	15	3.087(2.504–3.8060)	10.56	< 0.001	39.40%	0.064	Fixed-effect	0.711

ISSN: 1465-993X